CORT רווח נקי למניה ב-12 החודשים האחרונים corcept.com
The TTM fundamental earnings per share dynamics for Corcept Therapeutics (CORT) on GURU.Markets are based on Korlym sales, where the success of new molecules and patent disputes determine margins. High operating income provides the liquidity necessary for pipeline development, while the 1.28 mark serves as a key indicator metric. However, reliance on a single drug creates significant risks for the long-term predictability of cash flows.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_CORT_-_Corcept-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Corcept - רווח נקי למניה (EPS TTM) CORT (תקופה 04.07.2022 - 14.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Corcept Therapeutics Inc. (CORT)
Professional managers utilize fundamental filters to screen out assets where returns do not cover the weighted average cost of capital (WACC). This metric measures net profit, adjusted for issuance volume and discounted by cash flows, which, combined with the sales growth of Cushing's syndrome treatments at Corcept Therapeutics (CORT), allows for an assessment of real business efficiency via the rolling 12-month EPS.
